Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Free Cash Flow (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Free Cash Flow for 7 consecutive years, with -$95.1 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 23.92% to -$95.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$360.0 million through Dec 2025, down 3.44% year-over-year, with the annual reading at -$360.0 million for FY2025, 3.44% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$95.1 million at Beam Therapeutics, down from -$78.4 million in the prior quarter.
  • The five-year high for Free Cash Flow was $211.2 million in Q1 2022, with the low at -$120.5 million in Q1 2023.
  • Average Free Cash Flow over 5 years is -$51.5 million, with a median of -$79.0 million recorded in 2023.
  • Peak annual rise in Free Cash Flow hit 521.99% in 2022, while the deepest fall reached 2470.18% in 2022.
  • Over 5 years, Free Cash Flow stood at -$11.5 million in 2021, then tumbled by 874.82% to -$112.5 million in 2022, then surged by 192.04% to $103.5 million in 2023, then crashed by 174.13% to -$76.7 million in 2024, then decreased by 23.92% to -$95.1 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$95.1 million, -$78.4 million, and -$81.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.